CellSight Technologies

Executive Summary

CellSight Technologies is a San Francisco-based biotechnology company pioneering a novel PET imaging platform, VisAcT (18F-AraG), that enables in vivo visualization and quantification of activated T cells. Founded in 2016, the company addresses a critical unmet need in immunotherapy by providing a non-invasive tool to monitor T cell activation in real time. This technology has broad applications across immuno-oncology, autoimmune diseases, and neuroinflammation, allowing for improved patient selection, therapy monitoring, and safety assessment. By directly tracking immune responses, CellSight's platform could transform how clinicians evaluate the efficacy and toxicity of immunotherapies, potentially reducing trial failures and accelerating drug development. VisAcT has shown promise in early clinical studies for detecting T cell infiltration in tumors and inflammation sites, differentiating it from conventional imaging modalities. The company is advancing its lead candidate through clinical development for multiple indications, with a focus on oncology and autoimmune disorders. The market opportunity is substantial, given the rapid growth of immuno-oncology and the increasing need for biomarkers to guide treatment decisions. If successful, CellSight could become a standard-of-care tool for immunotherapy management, driving significant value for patients, physicians, and biopharma partners. The company's platform is also being explored for applications in CAR-T cell therapy monitoring and checkpoint inhibitor response prediction.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical trial results in immuno-oncology (e.g., melanoma or lung cancer)60% success
• H2 2026Strategic partnership or licensing deal with a major pharmaceutical company for autoimmune indications50% success
• Q2 2026FDA Breakthrough Device Designation or Investigational New Drug (IND) clearance for a new indication70% success